{"filing":{"accession_number":"0001193125-26-430977","cik":"0001783183","ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"d171570d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526430977/d171570d8k.htm"},"events":[{"id":37739,"run_id":34780,"accession_number":"0001193125-26-430977","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"Phathom disclosed litigation brought by BDR Pharmaceuticals challenging the FDA's June 6, 2025 decision granting Phathom's Citizen Petition regarding 10 years of NCE exclusivity for VOQUEZNA through May 3, 2032. The FDA has established a public docket to solicit comments on this matter, and a second ANDA filer (Saba Ilac) has indicated intent to consolidate its case with BDR's. This litigation directly threatens Phathom's regulatory exclusivity period for its lead product, making it material to investors assessing the company's competitive position and revenue protection.","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42549,"accession_number":"0001193125-26-430977","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Phathom disclosed litigation brought by BDR Pharmaceuticals challenging the FDA's June 6, 2025 decision granting Phathom's Citizen Petition regarding 10 years of NCE exclusivity for VOQUEZNA through May 3, 2032. The FDA has established a public docket to solicit comments on this matter, and a second ANDA filer (Saba Ilac) has indicated intent to consolidate its case with BDR's. This litigation directly threatens Phathom's regulatory exclusivity period for its lead product, making it material to investors assessing the company's competitive position and revenue protection.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:05:43.781275+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42549,"accession_number":"0001193125-26-430977","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Phathom disclosed litigation brought by BDR Pharmaceuticals challenging the FDA's June 6, 2025 decision granting Phathom's Citizen Petition regarding 10 years of NCE exclusivity for VOQUEZNA through May 3, 2032. The FDA has established a public docket to solicit comments on this matter, and a second ANDA filer (Saba Ilac) has indicated intent to consolidate its case with BDR's. This litigation directly threatens Phathom's regulatory exclusivity period for its lead product, making it material to investors assessing the company's competitive position and revenue protection.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:05:43.781275+00:00","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-10-26"}]}
